Related Experiment Videos
Improving and predicting radiosensitivity in muscle invasive bladder cancer
Alexandra J Colquhoun1, George D D Jones, Manar Al Moneef
1University Division of Urology, Leicester General Hospital, Department of Oncology, University of Leicester and University Department of Oncology, Leicester Royal Infirmary, Leicester, United Kingdom.
The Journal of Urology
|May 29, 2003
Summary
Improving outcomes for muscle invasive bladder cancer involves advanced radiation therapy techniques and radiosensitizing agents. Predicting tumor radiosensitivity can enhance bladder-sparing treatments, improving patient prognosis.
Area of Science:
- Uro-oncology
- Radiation Oncology
- Medical Oncology
Background:
- Muscle invasive bladder cancer presents a significant challenge with variable survival rates.
- Current treatment strategies often involve radical cystectomy or radiation therapy.
- Bladder preservation is a key goal in managing this malignancy.
Purpose of the Study:
- To review methods for improving outcomes in muscle invasive bladder cancer.
- To emphasize the role of radiation therapy as a bladder-preserving treatment.
- To explore advancements in radiosensitization for bladder cancer.
Main Methods:
- Literature search of MEDLINE and ISI Web of Science.
- Keywords: radiotherapy, radiosensitization, bladder neoplasia.
- Focus on current status of radiation therapy and radiosensitizing agents.
Main Results:
- Methods to improve outcomes include radiation therapy modifications and radiosensitizing agents.
- Conventional agents include accelerated radiotherapy with carbon dioxide, oxygen, and nicotinamide.
- Novel agents targeting oncogenic products and predictive assays are emerging.
Conclusions:
- Predicting tumor radiosensitivity is crucial for treatment optimization.
- Implementation of radiosensitizing techniques can improve radiation therapy outcomes.
- Bladder-sparing approaches using radiation therapy remain a viable option.